NCT05073120Completed
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
Source: ClinicalTrials.gov · Last updated 3 Jun 2025
Brief summary (registry, in English)
This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey assessed the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 103 (actual)
- First submitted
- 15 Sept 2021
- Start date
- Feb 2022
- Primary completion date
- Jun 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Metastatic breast cancer
- NCT number
- NCT05073120
What you commit to
- Study type: Observational
- Participants enrolled: 103
- From Feb 2022 to the primary completion date, Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or ICON.
Who the study is looking for
- Had prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months prior to completing the survey.
- Provided permission to share their anonymized responses in aggregate with EMA or NCAs, if requested.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.